ClinicalTrials.gg
Active, not recruitingNCT05329649Updated Jul 1, 2026

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

A Phase 3 interventional study of CTX001 in Sickle Cell Disease, Hydroxyurea Failure and Hydroxyurea Intolerance, sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 7 sites in 4 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
422nd of 559
13 · median 31
Started
2022
with 40 others
Phase 3
50 of 733
10 open now
Primary completion
2027-06
later than 78 of 182 live
Registered
586th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 422nd largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 50 in phase 3, reaches primary completion later than 78 of the 182 other live ones, and was the 586th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

03

Conditions studied

  • Sickle Cell Disease
  • Hydroxyurea Failure
  • Hydroxyurea Intolerance
  • Hemoglobinopathies
  • Hematological Diseases
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of severe SCD as defined by:
  • Documented SCD genotypes
  • History of at least two severe VOCs events per year for the previous two years prior to enrollment
  • Hydroxyurea (HU) failure unless HU intolerant
  • Eligible for stem cell transplant as per investigators judgment

Key Exclusion Criteria:

  • A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor
  • Prior hematopoietic stem cell transplant (HSCT).
  • and active bacterial, viral, fungal, or parasitic infection

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    CTX001

    CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.

    Biological: CTX001

Interventions

  • BiologicalCTX001

    Administered by intravenous infusion following myeloablative conditioning with busulfan.

    Also known as: Exagamglogene autotemcel, Exa-cel

06

What researchers measure

Primary outcomes

  1. Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12)

    Time frame: Up to 24 Months After CTX001 Infusion

Secondary outcomes

  1. Proportion of Participants Free from Inpatient Hospitalization for Severe VOCs for at Least 12 Months (HF12)

    Time frame: Up to 24 Months After CTX001 Infusion

  2. Relative Reduction in Annualized Rate of Severe VOCs

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  3. Duration of Severe VOC Free in Participants who Have Achieved VF12

    Time frame: Up to 24 Months After CTX001 Infusion

  4. Relative Reduction in Annualized Rate of Inpatient Hospitalizations for Severe VOCs

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  5. Proportion of Participants With Sustained Fetal Hemoglobin (HbF) ≥20 Percent (%) for at Least 3 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  6. Proportion of Participants With Sustained HbF ≥20% for at Least 6 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  7. Proportion of Participants With Sustained HbF ≥20% for at Least 12 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  8. Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  9. Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  10. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion

  11. Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count [ANC] ≥500 per Microliter [mcgL] on 3 Different Days)

    Time frame: Within 42 Days After CTX001 Infusion

  12. Time to Engraftment

    Time frame: Up to 24 Months After CTX001 Infusion

  13. Incidence of Transplant-related Mortality (TRM) Within 100 Days After CTX001 Infusion

    Time frame: Within 100 Days After CTX001 infusion

  14. Incidence of TRM Within 12 Months After CTX001 Infusion

    Time frame: Within 12 Months After Infusion

  15. Incidence of All-cause Mortality

    Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion

  16. Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  17. Proportion of Participants With Sustained HbF ≥30% for at Least 3 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  18. Proportion of Participants With Sustained HbF ≥30% for at Least 6 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  19. Proportion of Participants With Sustained HbF ≥30% for at Least 12 Months

    Time frame: Up to 24 Months After CTX001 Infusion

  20. Time for Participants to Reach HbF ≥20%

    Time frame: Up to 24 Months After CTX001 Infusion

  21. Time for Participants to Reach HbF ≥30%

    Time frame: Up to 24 Months After CTX001 Infusion

  22. Relative Reduction from Baseline in Annualized Volume and Episodes of RBC Transfusions for SCD-related indications starting after Month 12 post-CTX001 infusion

    Time frame: Up to 24 Months After CTX001 Infusion

  23. HbF Concentrations Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  24. Hemoglobin (Hb) Concentrations Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  25. Change in Reticulocyte Count Over Time

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  26. Change in Indirect Bilirubin Over Time

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  27. Change in Haptoglobin Over Time

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  28. Proportion of Participants with Detectable Haptoglobin Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  29. Change in Lactate Dehydrogenase (LDH) Over Time

    Time frame: From Baseline (Pre-infusion) up to 24 Months After CTX001 Infusion

  30. Proportion of Participants with Normalized LDH Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

07

Study locations

7 sites
08

References and documents

Publications

  • Frangoul H, de la Fuente J, Chopra Y, Meisel R, Amrolia PJ, Algeri M, Sharma A, Cappellini MD, Corbacioglu S, Kattamis A, Lobitz S, de Montalembert M, Rondelli D, Sheth S, Steinberg MH, Walters MC, Boerner K, Liu T, Zairis S, Hobbs W, Grupp SA, Locatelli F; CLIMB THAL-141 and CLIMB SCD-151 Study Groups. Exa-cel in Children with Transfusion-Dependent beta-Thalassemia or Sickle Cell Disease. N Engl J Med. 2026 Jun 11. doi: 10.1056/NEJMoa2603387. Online ahead of print. PubMed 42274009 ↗

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.

Of 35 phase 3 interventional studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 61. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 15, 2022
StartActual
May 2, 2022
Primary completionEst.
Jun 6, 2027
CompletionEst.
Jun 6, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05329649
Collaborators
CRISPR Therapeutics
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
May 2, 2022
Primary completion
Jun 6, 2027 (estimated)
Completion
Jun 6, 2027 (estimated)
Last update
Jul 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exagamglogene autotemcel

Start the discussion